NEXVET BIOPHARMA PLC (NVET) financial statements (2021 and earlier)

Company profile

Business Address UNIT 5, SRAGH TECHNOLOGY PARK
TULLAMORE , CO. OFFALY, R35 FR98
State of Incorp.
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2017
Q3
12/31/2016
Q2
9/30/2016
Q1
6/30/2016
Q4
3/31/2016
Q3
12/31/2015
Q2
9/30/2015
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15202531374348
Cash and cash equivalents15202531374348
Receivables1100001
Prepaid expense1100   
Other current assets0010   
Other undisclosed current assets2132221
Total current assets:19232935404550
Noncurrent Assets
Nontrade receivables      0
Property, plant and equipment5555433
Intangible assets, net (including goodwill)0000000
Intangible assets, net (excluding goodwill)0000000
Prepaid expense0000000
Deferred costs0000  0
Other undisclosed noncurrent assets110000(0)
Total noncurrent assets:6665433
TOTAL ASSETS:25293440444953
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3234332
Accounts payable1112211
Accrued liabilities0010000
Employee-related liabilities1112111
Deferred revenue and credits0000000
Other undisclosed current liabilities1111222
Total current liabilities:4345544
Noncurrent Liabilities
Liabilities, other than long-term debt0000000
Deferred revenue and credits0000000
Accounts payable and accrued liabilities00000  
Other undisclosed noncurrent liabilities0000000
Total noncurrent liabilities:0000000
Total liabilities:4345554
Stockholders' equity
Stockholders' equity attributable to parent, including:21263135394449
Common stock1111111
Additional paid in capital84838282828181
Accumulated other comprehensive loss(5)(5)(5)(5)(5)(5)(6)
Accumulated deficit(60)(54)(48)(43)(39)(33)(28)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:21263135394449
TOTAL LIABILITIES AND EQUITY:25293440444953

Income statement (P&L) ($ in millions)

3/31/2017
Q3
12/31/2016
Q2
9/30/2016
Q1
6/30/2016
Q4
3/31/2016
Q3
12/31/2015
Q2
9/30/2015
Q1
Gross profit:  (0)0  (1)
Operating expenses(7)(5)(6)(5)(6)(6)(6)
Other undisclosed operating income (loss)  0(0)  1
Operating loss:(7)(5)(6)(5)(6)(6)(6)
Nonoperating income (expense)0(1)(0)0(0)(1)1
Investment income, nonoperating0000000
Foreign currency transaction gain (loss), before tax0(1)(0)0(0)(1)1
Net loss:(7)(6)(6)(5)(6)(6)(5)
Other undisclosed net income attributable to parent1111001
Net loss available to common stockholders, diluted:(6)(5)(5)(4)(6)(6)(4)

Comprehensive Income ($ in millions)

3/31/2017
Q3
12/31/2016
Q2
9/30/2016
Q1
6/30/2016
Q4
3/31/2016
Q3
12/31/2015
Q2
9/30/2015
Q1
Net loss:(7)(6)(6)(5)(6)(6)(5)
Comprehensive loss:(7)(6)(6)(5)(6)(6)(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent111111(1)
Comprehensive loss, net of tax, attributable to parent:(6)(5)(5)(4)(6)(5)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: